Azenta

AZTA on Nasdaq. Azenta sells sample storage and lab services to drug and biotech researchers. Market value $2.0bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to September 2026.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

See Industrials stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
1.5%low

For every $100 of what the whole company costs, it produced $1.46 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to September 2026
n/a

The filings do not give us enough to work this out.

Quality score: 47 of 100. Price score: 8 of 100. Our list needs 70 on quality and 60 on price.

$44.80 a share, 181% above its 1-year low

Over the past year the price has ranged from $15.93 to $50.06.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.5
-0.0
0.0
0.0
0.0
20222023202420252026
Revenue
$555m$551m$573m$594m$622m
Operating margin
-4.5%-11.1%-8.9%-4.5%-28.1%
Debt to equity
n/an/an/an/an/a
Shares outstanding
0.06bn0.05bn0.05bn0.04bn0.04bn

Health checks

  • Free cash flow positive3 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)4 of 8 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsSlow, 3.9% a year
  • Buying back its own sharesYes, 30% fewer since 2022

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $167 million last quarter, up 5% on a year ago.
  • Profit: $7 million, down 87% on a year ago.
  • It loses 28 cents on each $1 of sales, compared with 5 cents a year earlier.
  • Spare cash over the past 12 months: $27 million, down from $38 million.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$147m
March 2025$143m
June 2025$144m
September 2025$159m
December 2025$149m
March 2026$145m
June 2026$161m
September 2026$167m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$11m
March 2025-$48m
June 2025-$48m
September 2025$51m
December 2025-$15m
March 2026-$161m
June 2026$2m
September 2026$7m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
19 November 2026
Next quarterly (estimated, 10-Q)
5 November 2026

Who owns it

3 long-term investors we follow own it, down from 4 last quarter. 249 funds in all.

Jun '25
Dec '25
Jun '26

Sold out this quarter

Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

1 investor owns more than 5%.

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 2 insiders bought $171,896 of shares on the open market.

  • Starr Ephraim
    SVP, Gen Counsel & Secretary
    Bought
    Date
    31 July 2026
    Shares
    335
    Price
    $24.17
    Value
    $8,096
  • Cornog William L
    Director
    Bought
    Date
    18 May 2026
    Shares
    10,000
    Price
    $16.38
    Value
    $163,800

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 19 Nov 2026, and no later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from

The company just told the SEC about a big change. The deep dive shows what it means for the price you pay.

Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.